{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:10:22Z","timestamp":1787022622267,"version":"build-2736575974"},"reference-count":44,"publisher":"Walter de Gruyter GmbH","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2017-0017_s_008_w2aab3b7c10b1b6b1aab1c15b1Aa\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has changed treatment for selected patients with peritoneal metastases (PM) arising from appendiceal, colorectal, epithelial ovarian, primary peritoneal and gastric cancers. However, the results of CRS with HIPEC remain unclear in PM from other tumor histologies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2017-0017_s_009_w2aab3b7c10b1b6b1aab1c15b2Aa\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We report a series of 10 patients who underwent CRS and HIPEC between 2006 and 2015, for PM arising from uncommon tumor origins.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2017-0017_s_010_w2aab3b7c10b1b6b1aab1c15b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ten patients with PM from uncommon tumor origins underwent CRS and HIPEC. Median age was 46.5 years. Two patients had ovarian Sertoli-Leydig cell tumors (SLCT) and two had small bowel adenocarcinomas. The other histologies included: ovarian transitional cell carcinoma, ovarian granulosa cell tumor, endometroid adenocarcinoma, endocervical adenocarcinoma, synovial sarcoma, and ovarian leiomyosarcoma. Median peritoneal cancer index was 9 (2\u201318) and complete cytoreduction was achieved for all patients. Median follow-up was 14 months (2\u2013100), and median time to recurrence from CRS and HIPEC was 16.0 months by Kaplan\u2013Meier estimate. Four patients remain alive and disease-free, five are alive with disease, and one had died with disease. Median survival was not reached.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2017-0017_s_011_w2aab3b7c10b1b6b1aab1c15b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Eight of ten patients with peritoneal metastases in the above rare indications survived 10 months or more after CRS and HIPEC. These encouraging results are a rationale for prospective clinical trials in these tumor histologies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2017-0017","type":"journal-article","created":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T06:06:17Z","timestamp":1503554777000},"page":"129-136","source":"Crossref","is-referenced-by-count":10,"title":["Uncommon indications for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy"],"prefix":"10.1515","volume":"2","author":[{"given":"Francis Zheng Yi","family":"Yee","sequence":"first","affiliation":[{"name":"Yong Loo Lin School of Medicine , National University of Singapore , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace Hwei Ching","family":"Tan","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology , National Cancer Centre Singapore , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claramae Shulyn","family":"Chia","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology , National Cancer Centre Singapore , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khee Chee","family":"Soo","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology , National Cancer Centre Singapore , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa Ching Ching","family":"Teo","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology , National Cancer Centre Singapore , Singapore , Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2017,8,24]]},"reference":[{"key":"2025120909192902966_j_pp-2017-0017_ref_001_w2aab3b7c10b1b6b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Elias D, Goere D, Dumont F, Honore C, Dartigues P, Stoclin A et al. Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. Eur J Cancer (Oxford, England: 1990) 2014;50(2):332\u2013340.","DOI":"10.1016\/j.ejca.2013.09.024"},{"key":"2025120909192902966_j_pp-2017-0017_ref_002_w2aab3b7c10b1b6b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 2010;116(24):5608\u20135618.","DOI":"10.1002\/cncr.25356"},{"key":"2025120909192902966_j_pp-2017-0017_ref_003_w2aab3b7c10b1b6b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Gusani NJ, Cho SW, Colovos C, Seo S, Franko J, Richard SD et al. Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. Ann Surg Oncol 2008;15(3):754\u2013763.","DOI":"10.1245\/s10434-007-9701-4"},{"key":"2025120909192902966_j_pp-2017-0017_ref_004_w2aab3b7c10b1b6b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH. Surgical management of peritoneal carcinosis: diagnosis, prevention and treatment. Langenbecks Arch Chir 1988;373(3):189\u2013196.","DOI":"10.1007\/BF01274232"},{"key":"2025120909192902966_j_pp-2017-0017_ref_005_w2aab3b7c10b1b6b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH. Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: the Washington Cancer Institute approach. Expert Opin Pharmacother 2009;10(12):1965\u20131977.","DOI":"10.1517\/14656560903044974"},{"key":"2025120909192902966_j_pp-2017-0017_ref_006_w2aab3b7c10b1b6b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol: Off J Eur Soc Med Oncol\/ESMO 2007;18(5):827\u2013834.","DOI":"10.1093\/annonc\/mdl428"},{"key":"2025120909192902966_j_pp-2017-0017_ref_007_w2aab3b7c10b1b6b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 2006;7(1):69\u201376.","DOI":"10.1016\/S1470-2045(05)70539-8"},{"key":"2025120909192902966_j_pp-2017-0017_ref_008_w2aab3b7c10b1b6b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al. Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol 1982;5(6):649\u2013655.","DOI":"10.1097\/00000421-198212000-00014"},{"key":"2025120909192902966_j_pp-2017-0017_ref_009_w2aab3b7c10b1b6b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996;82:359\u2013374.","DOI":"10.1007\/978-1-4613-1247-5_23"},{"key":"2025120909192902966_j_pp-2017-0017_ref_010_w2aab3b7c10b1b6b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995;221(1):29\u201342.","DOI":"10.1097\/00000658-199501000-00004"},{"key":"2025120909192902966_j_pp-2017-0017_ref_011_w2aab3b7c10b1b6b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Tan GH, Ong WS, Chia CS, Tham CK, Soo KC, Teo MC Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference? International Journal of Hyperthermia: The Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group. 2016:1\u20138.","DOI":"10.3109\/02656736.2015.1135485"},{"key":"2025120909192902966_j_pp-2017-0017_ref_012_w2aab3b7c10b1b6b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Younan R, Kusamura S, Baratti D, Cloutier AS, Deraco M. Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy. J Surg Oncol 2008;98(4):253\u2013257.","DOI":"10.1002\/jso.21057"},{"key":"2025120909192902966_j_pp-2017-0017_ref_013_w2aab3b7c10b1b6b1ab2b2c13Aa","unstructured":"DiSario JA, Burt RW, Vargas H, McWhorter WP. Small bowel cancer: epidemiological and clinical characteristics from a population-based registry. Am J Gastroenterol 1994;89(5):699\u2013701."},{"key":"2025120909192902966_j_pp-2017-0017_ref_014_w2aab3b7c10b1b6b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"Frost DB, Mercado PD, Tyrell JS. Small bowel cancer: a 30-year review. Ann Surg Oncol 1994;1(4):290\u2013295.","DOI":"10.1007\/BF02303567"},{"key":"2025120909192902966_j_pp-2017-0017_ref_015_w2aab3b7c10b1b6b1ab2b2c15Aa","unstructured":"Weiss NS, Yang CP. Incidence of histologic types of cancer of the small intestine. J Natl Cancer Inst 1987;78(4):653\u2013656."},{"key":"2025120909192902966_j_pp-2017-0017_ref_016_w2aab3b7c10b1b6b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Jacks SP, Hundley JC, Shen P, Russell GB, Levine EA. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma. J Surg Oncol 2005;91(2):112\u2013117; discussion 8-9.","DOI":"10.1002\/jso.20296"},{"key":"2025120909192902966_j_pp-2017-0017_ref_017_w2aab3b7c10b1b6b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"Marchettini P, Sugarbaker PH. Mucinous adenocarcinoma of the small bowel with peritoneal seeding. Eur J Surg Oncology: J Eur Soc Surg Oncol Br Assoc Surg Oncol 2002;28(1):19\u201323.","DOI":"10.1053\/ejso.2001.1196"},{"key":"2025120909192902966_j_pp-2017-0017_ref_018_w2aab3b7c10b1b6b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"Sun Y, Shen P, Stewart JH, Russell GB, Levine EA. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma. Am Surg 2013;79(6):644\u2013648.","DOI":"10.1177\/000313481307900629"},{"key":"2025120909192902966_j_pp-2017-0017_ref_019_w2aab3b7c10b1b6b1ab2b2c19Aa","doi-asserted-by":"crossref","unstructured":"Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88(2):358\u2013363.","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O"},{"key":"2025120909192902966_j_pp-2017-0017_ref_020_w2aab3b7c10b1b6b1ab2b2c20Aa","doi-asserted-by":"crossref","unstructured":"Shen P, Stewart J, Levine EA. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: non-colorectal indications. Curr Probl Cancer 2009;33(3):168\u2013193.","DOI":"10.1016\/j.currproblcancer.2009.06.005"},{"key":"2025120909192902966_j_pp-2017-0017_ref_021_w2aab3b7c10b1b6b1ab2b2c21Aa","doi-asserted-by":"crossref","unstructured":"Turrini O, Lambaudie E, Faucher M, Viret F, Blache JL, Houvenaeghel G et al. Initial experience with hyperthermic intraperitoneal chemotherapy. Arch Surg 2012;147(10):919\u2013923.","DOI":"10.1001\/archsurg.2012.988"},{"key":"2025120909192902966_j_pp-2017-0017_ref_022_w2aab3b7c10b1b6b1ab2b2c22Aa","doi-asserted-by":"crossref","unstructured":"Randle RW, Swett KR, Shen P, Stewart JH, Levine EA, Votanopoulos KI. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal sarcomatosis. Am Surg 2013;79(6):620\u2013624.","DOI":"10.1177\/000313481307900624"},{"key":"2025120909192902966_j_pp-2017-0017_ref_023_w2aab3b7c10b1b6b1ab2b2c23Aa","doi-asserted-by":"crossref","unstructured":"Honore C, Goere D, Macovei R, Colace L, Benhaim L, Elias D. Peritoneal carcinomatosis from unusual cancer origins: is there a role for hyperthermic intraperitoneal chemotherapy? J Visc Surg 2016;153(2):101\u2013107.","DOI":"10.1016\/j.jviscsurg.2015.11.010"},{"key":"2025120909192902966_j_pp-2017-0017_ref_024_w2aab3b7c10b1b6b1ab2b2c24Aa","doi-asserted-by":"crossref","unstructured":"Cardi M, Sammartino P, Mingarelli V, Sibio S, Accarpio F, Biacchi D et al. Cytoreduction and HIPEC in the treatment of \u201cunconventional\u201d secondary peritoneal carcinomatosis. World J Surg Oncol 2015;13:305.","DOI":"10.1186\/s12957-015-0703-6"},{"key":"2025120909192902966_j_pp-2017-0017_ref_025_w2aab3b7c10b1b6b1ab2b2c25Aa","doi-asserted-by":"crossref","unstructured":"Van Oudheusden TR, Lemmens VE, Braam HJ, Van Ramshorst B, Meijerink J, Te Velde EA et al. Peritoneal metastases from small bowel cancer: results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in The Netherlands. Surgery 2015;157(6):1023\u20131027.","DOI":"10.1016\/j.surg.2015.01.021"},{"key":"2025120909192902966_j_pp-2017-0017_ref_026_w2aab3b7c10b1b6b1ab2b2c26Aa","doi-asserted-by":"crossref","unstructured":"Elias D, Glehen O, Pocard M, Quenet F, Goere D, Arvieux C et al. A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg 2010;251(5):896\u2013901.","DOI":"10.1097\/SLA.0b013e3181d9765d"},{"key":"2025120909192902966_j_pp-2017-0017_ref_027_w2aab3b7c10b1b6b1ab2b2c27Aa","doi-asserted-by":"crossref","unstructured":"Czaykowski P, Hui D. Chemotherapy in small bowel adenocarcinoma: 10-year experience of the British Columbia Cancer Agency. Clin Oncol (Royal College of Radiologists (Great Britain)) 2007;19(2):143\u2013149.","DOI":"10.1016\/j.clon.2006.12.001"},{"key":"2025120909192902966_j_pp-2017-0017_ref_028_w2aab3b7c10b1b6b1ab2b2c28Aa","doi-asserted-by":"crossref","unstructured":"Koo DH, Yun SC, Hong YS, Ryu MH, Lee JL, Chang HM et al. Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study. BMC Cancer 2011;11:205.","DOI":"10.1186\/1471-2407-11-205"},{"key":"2025120909192902966_j_pp-2017-0017_ref_029_w2aab3b7c10b1b6b1ab2b2c29Aa","doi-asserted-by":"crossref","unstructured":"Locher C, Malka D, Boige V, Lebray P, Elias D, Lasser P et al. Combination chemotherapy in advanced small bowel adenocarcinoma. Oncology 2005;69(4):290\u2013294.","DOI":"10.1159\/000089678"},{"key":"2025120909192902966_j_pp-2017-0017_ref_030_w2aab3b7c10b1b6b1ab2b2c30Aa","doi-asserted-by":"crossref","unstructured":"Quirk JT, Natarajan N. Ovarian cancer incidence in the United States, 1992-1999. Gynecol Oncol 2005;97(2):519\u2013523.","DOI":"10.1016\/j.ygyno.2005.02.007"},{"key":"2025120909192902966_j_pp-2017-0017_ref_031_w2aab3b7c10b1b6b1ab2b2c31Aa","doi-asserted-by":"crossref","unstructured":"Lantzsch T, Stoerer S, Lawrenz K, Buchmann J, Strauss HG, Koelbl H. Sertoli-Leydig cell tumor. Arch Gynecol Obstet 2001;264(4):206\u2013208.","DOI":"10.1007\/s004040000114"},{"key":"2025120909192902966_j_pp-2017-0017_ref_032_w2aab3b7c10b1b6b1ab2b2c32Aa","doi-asserted-by":"crossref","unstructured":"Young RH, Scully RE. Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases. Am J Surg Pathol 1985;9(8):543\u2013569.","DOI":"10.1097\/00000478-198508000-00001"},{"key":"2025120909192902966_j_pp-2017-0017_ref_033_w2aab3b7c10b1b6b1ab2b2c33Aa","unstructured":"Tandon R, Goel P, Saha PK, Takkar N, Punia R. A rare ovarian tumor \u2013 Sertoli-leydig cell tumor with heterologous element. Medscape Gen Med 2007;9(4):44."},{"key":"2025120909192902966_j_pp-2017-0017_ref_034_w2aab3b7c10b1b6b1ab2b2c34Aa","unstructured":"Li B, Wu LY, Zhang WH, Li L, Ma SK, Liu LY. [Clinical analysis of 11 cases of ovarian Setoli-Leydig cell tumor]. Zhonghua Fu Chan Ke Za Zhi 2004;39(5):334\u2013337."},{"key":"2025120909192902966_j_pp-2017-0017_ref_035_w2aab3b7c10b1b6b1ab2b2c35Aa","doi-asserted-by":"crossref","unstructured":"Sigismondi C, Gadducci A, Lorusso D, Candiani M, Breda E, Raspagliesi F et al. Ovarian Sertoli-Leydig cell tumors. a retrospective MITO study. Gynecol Oncol 2012;125(3):673\u2013676.","DOI":"10.1016\/j.ygyno.2012.03.024"},{"key":"2025120909192902966_j_pp-2017-0017_ref_036_w2aab3b7c10b1b6b1ab2b2c36Aa","doi-asserted-by":"crossref","unstructured":"Schneider DT, Orbach D, Cecchetto G, Stachowicz-Stencel T, Brummel B, Brecht IB et al. Ovarian sertoli leydig cell tumours in children and adolescents: an analysis of the European cooperative study group on pediatric rare tumors (EXPeRT). Eur J Cancer (Oxford, England : 1990) 2015;51(4):543\u2013550.","DOI":"10.1016\/j.ejca.2014.11.013"},{"key":"2025120909192902966_j_pp-2017-0017_ref_037_w2aab3b7c10b1b6b1ab2b2c37Aa","doi-asserted-by":"crossref","unstructured":"Gui T, Cao D, Shen K, Yang J, Zhang Y, Yu Q et al. A clinicopathological analysis of 40 cases of ovarian Sertoli-Leydig cell tumors. Gynecol Oncol 2012;127(2):384\u2013389.","DOI":"10.1016\/j.ygyno.2012.07.114"},{"key":"2025120909192902966_j_pp-2017-0017_ref_038_w2aab3b7c10b1b6b1ab2b2c38Aa","doi-asserted-by":"crossref","unstructured":"Hayes-Jordan A, Lopez C, Green HL, Xiao LC, Huh W, Herzog CE. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric ovarian tumors: a novel treatment approach. Pediatr Surg Int 2016;32(1):71\u201373.","DOI":"10.1007\/s00383-015-3814-9"},{"key":"2025120909192902966_j_pp-2017-0017_ref_039_w2aab3b7c10b1b6b1ab2b2c39Aa","unstructured":"Evans AT, 3rd, Gaffey TA, Malkasian GD, Jr., Annegers JF. Clinicopathologic review of 118 granulosa and 82 theca cell tumors. Obstet Gynecol 1980;55(2):231\u2013238."},{"key":"2025120909192902966_j_pp-2017-0017_ref_040_w2aab3b7c10b1b6b1ab2b2c40Aa","doi-asserted-by":"crossref","unstructured":"Lee IH, Choi CH, Hong DG, Song JY, Kim YJ, Kim KT et al. Clinicopathologic characteristics of granulosa cell tumors of the ovary: a multicenter retrospective study. J Gynecol Oncol 2011;22(3):188\u2013195.","DOI":"10.3802\/jgo.2011.22.3.188"},{"key":"2025120909192902966_j_pp-2017-0017_ref_041_w2aab3b7c10b1b6b1ab2b2c41Aa","doi-asserted-by":"crossref","unstructured":"Al-Badawi IA, Abu-Zaid A, Azzam A, AlOmar O, AlHusaini H, Amin T. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for management of recurrent\/relapsed ovarian granulosa cell tumor: a single-center experience. J Obstet Gynaecol Res 2014;40(9):2066\u20132075.","DOI":"10.1111\/jog.12460"},{"key":"2025120909192902966_j_pp-2017-0017_ref_042_w2aab3b7c10b1b6b1ab2b2c42Aa","unstructured":"Canbay E, Ishibashi H, Sako S, Miyata R, Nishino E, Yonemura Y. Management of peritoneal dissemination of recurrences granulosa cell tumor of the ovary. Gan Kagaku Ryoho Cancer Chemotherapy 2012;39(12):2435\u20132437."},{"key":"2025120909192902966_j_pp-2017-0017_ref_043_w2aab3b7c10b1b6b1ab2b2c43Aa","doi-asserted-by":"crossref","unstructured":"Lee YK, Park NH, Kim JW, Song YS, Kang SB, Lee HP. Characteristics of recurrence in adult-type granulosa cell tumor. Int J Gynecol Cancer 2008;18(4):642\u2013647.","DOI":"10.1111\/j.1525-1438.2007.01065.x"},{"key":"2025120909192902966_j_pp-2017-0017_ref_044_w2aab3b7c10b1b6b1ab2b2c44Aa","doi-asserted-by":"crossref","unstructured":"Gouy S, Uzan C, Pautier P, Lhomme C, Duvillard P, Morice P. Results of oxaliplatin-based hyperthermic intraperitoneal chemotherapy in recurrent ovarian granulosa cell tumors. Eur J Obstet Gynecol Reprod Biol 2013;170(2):464\u2013467.","DOI":"10.1016\/j.ejogrb.2013.06.041"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/2\/3\/article-p129.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0017\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0017\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T09:51:38Z","timestamp":1765273898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0017\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,24]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,9,1]]},"published-print":{"date-parts":[[2017,8,31]]}},"alternative-id":["10.1515\/pp-2017-0017"],"URL":"https:\/\/doi.org\/10.1515\/pp-2017-0017","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8,24]]}}}